


IHCP *bulletin*

INDIANA HEALTH COVERAGE PROGRAMS BT201525 APRIL 16, 2015

IHCP suspends prior authorization for HIV/AIDS drug therapies

Effective immediately, the Indiana Family and Social Services Administration (FSSA) is suspending the prior authorization (PA) requirements for the following human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) drug therapies:

- TRIUMEQ (dolutegravir/abacavir/lamivudine)
- TRUVADA (emtricitabine/tenofovir)
- TIVICAY (dolutegravir)
- ISENTRESS (raltegravir)




This action applies to services rendered to all Indiana Health Coverage Programs (IHCP) members enrolled in any IHCP program, including those operated by contracted managed care entities such as the Healthy Indiana Plan (HIP) program.

QUESTIONS?

If you have questions about this publication, please contact Customer Assistance at 1-800-577-1278.

SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope here or on the pages of indianamedicaid.com.



COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please [download them](#) from indianamedicaid.com.

TO PRINT

A [printer-friendly version](#) of this publication, in black and white and without graphics, is available for your convenience.